After Medline pulled off a massive $6.26 billion IPO late last year, the company now finds itself facing serious concerns being leveled by the FDA. | After Medline pulled off a massive $6.26 billion ...

Oncology biotech Akari Therapeutics has announced a partnership with WuXi XDC, an antibody-drug conjugate (ADC) development ...

Following a research collaboration established in 2021, Astellas Pharma has reached an agreement to license a Dyno ...

After entering 2026 hungry for deals, Gilead Sciences has wasted no time eating its fill. | After entering 2026 hungry for ...

Jeito Capital has hailed the $1.2 billion it has secured as the “largest raise ever achieved” by an independent biopharma-focused European fund. | Jeito Capital has hailed the $1.2 billion it has ...

Despite signing a deal potentially worth $2.1 billion, Vivtex Therapeutics CEO Thomas von Erlach, Ph.D., refuses to rest on ...

Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch ...

When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...

Owlet is quickly rearranging its nest as Jonathan Harris has resigned, effective immediately, as president and CEO of the ...

AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI ...

Fortrea is expanding its capabilities with a suite of AI-powered technologies designed to automate workflows, streamline ...

Eli Lilly has handed AC Immune 10 million Swiss francs ($12.5 million) to expand their Alzheimer’s disease collaboration as a candidate moves closer to the clinic. The U.S. pharma first tapped up AC ...